FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W185032011> ?p ?o ?g. }

• W185032011 endingPage "5551" @default.
• W185032011 startingPage "5551" @default.
• W185032011 abstract "5551 Background: The standard treatment of locally advanced undifferentiated carcinoma of nasopharyngeal type (UCNT) is cisplatin based chemotherapy followed by locoregional radiotherapy. The purpose of this study is to assess the antitumor activity and toxicity of a new neoadjuvant chemotherapy regimen combining docetaxel (D) and cisplatin (C). Patients and Methods: Previously untreated patients (pts) with histologically diagnosed locally advanced UCNT (Stages IVA and IVB TNM/UICC 1997) received D 75 mg/m2 and C 75 mg/m2 both on day 1, cycles were repeated every 21 days. Every pts received three cycles in a neoadjuvant setting before radiotherapy (4 to 6 weeks after the third cycle of DC). Pts were evaluated by clinical examination, CT scan of nasopharynx and nasofibroscopy with biopsy. Primary end points were tumor response and disease free survival (DFS) Results: Toxicity, tumor response and survival over one year were assessable in all pts. There are 75 pts (54 male, 21 female) with a median age of 41 years (range 18 - 69) and a WHO performance status of 0 - 1 in 71 pts, 2 in 4 pts. 19 pts had stage IVA and 56 pts had stage IVB. After 225 cycles, grade 3 & 4 toxicity (WHO) were: neutropenia (12%), febrile neutropenia (2%), anemia (1%), nausea and vomiting (23%), diarrhea (8%), mucositis (1%), reversible alopecia (70%). Two pts had onycolysis. Response rates for the 75 pts were: complete pathologic response 37% (28 pts), partial response 52% (39 pts), stable disease 8% (6 pts) and progression 3% (2 pts). The overall response rate (ORR) was 90%. 72 pts had complete response after radiotherapy and one patient had stable disease. 23 patients had recurrence: 19 locoregional, and 4 metastatic (2 with bone metastasis, 1 hepatic metastasis and 1 cerebral metastasis). DFS and overall survival at 1 year were respectively 69% and 72%. Multivariate analysis of prognostic factors revealed that tumor stage was independently related to poor DFS. For stage IVA and IVB DFS was 13.89 and 17.22 months respectively (p=0.02). Conclusion: DC is an effective regimen with an acceptable safety profile in locally advanced UCNT. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis, sanofi-aventis" @default.
• W185032011 created "2016-06-24" @default.
• W185032011 creator A5006585898 @default.
• W185032011 creator A5022146765 @default.
• W185032011 creator A5037285054 @default.
• W185032011 creator A5050881855 @default.
• W185032011 creator A5054385601 @default.
• W185032011 creator A5057081725 @default.
• W185032011 creator A5063576946 @default.
• W185032011 creator A5065744880 @default.
• W185032011 creator A5074092300 @default.
• W185032011 date "2005-06-01" @default.
• W185032011 modified "2023-09-27" @default.
• W185032011 title "A phase II trial of docetaxel and cisplatin combination in patients with locally advanced undifferentiated carcinoma of the nasopharynx: updated results" @default.
• W185032011 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.5551" @default.
• W185032011 hasPublicationYear "2005" @default.
• W185032011 type Work @default.
• W185032011 sameAs 185032011 @default.
• W185032011 citedByCount "0" @default.
• W185032011 crossrefType "journal-article" @default.
• W185032011 hasAuthorship W185032011A5006585898 @default.
• W185032011 hasAuthorship W185032011A5022146765 @default.
• W185032011 hasAuthorship W185032011A5037285054 @default.
• W185032011 hasAuthorship W185032011A5050881855 @default.
• W185032011 hasAuthorship W185032011A5054385601 @default.
• W185032011 hasAuthorship W185032011A5057081725 @default.
• W185032011 hasAuthorship W185032011A5063576946 @default.
• W185032011 hasAuthorship W185032011A5065744880 @default.
• W185032011 hasAuthorship W185032011A5074092300 @default.
• W185032011 hasConcept C126322002 @default.
• W185032011 hasConcept C141071460 @default.
• W185032011 hasConcept C143998085 @default.
• W185032011 hasConcept C2776694085 @default.
• W185032011 hasConcept C2777063308 @default.
• W185032011 hasConcept C2778248108 @default.
• W185032011 hasConcept C2778496288 @default.
• W185032011 hasConcept C2778850193 @default.
• W185032011 hasConcept C2780580376 @default.
• W185032011 hasConcept C2781190966 @default.
• W185032011 hasConcept C2781413609 @default.
• W185032011 hasConcept C31760486 @default.
• W185032011 hasConcept C509974204 @default.
• W185032011 hasConcept C71924100 @default.
• W185032011 hasConcept C90924648 @default.
• W185032011 hasConceptScore W185032011C126322002 @default.
• W185032011 hasConceptScore W185032011C141071460 @default.
• W185032011 hasConceptScore W185032011C143998085 @default.
• W185032011 hasConceptScore W185032011C2776694085 @default.
• W185032011 hasConceptScore W185032011C2777063308 @default.
• W185032011 hasConceptScore W185032011C2778248108 @default.
• W185032011 hasConceptScore W185032011C2778496288 @default.
• W185032011 hasConceptScore W185032011C2778850193 @default.
• W185032011 hasConceptScore W185032011C2780580376 @default.
• W185032011 hasConceptScore W185032011C2781190966 @default.
• W185032011 hasConceptScore W185032011C2781413609 @default.
• W185032011 hasConceptScore W185032011C31760486 @default.
• W185032011 hasConceptScore W185032011C509974204 @default.
• W185032011 hasConceptScore W185032011C71924100 @default.
• W185032011 hasConceptScore W185032011C90924648 @default.
• W185032011 hasIssue "16_suppl" @default.
• W185032011 hasLocation W1850320111 @default.
• W185032011 hasOpenAccess W185032011 @default.
• W185032011 hasPrimaryLocation W1850320111 @default.
• W185032011 hasRelatedWork W1988518947 @default.
• W185032011 hasRelatedWork W2014768677 @default.
• W185032011 hasRelatedWork W2025458965 @default.
• W185032011 hasRelatedWork W2084246274 @default.
• W185032011 hasRelatedWork W2104253325 @default.
• W185032011 hasRelatedWork W2106964779 @default.
• W185032011 hasRelatedWork W2243375749 @default.
• W185032011 hasRelatedWork W2981548069 @default.
• W185032011 hasRelatedWork W3005277898 @default.
• W185032011 hasRelatedWork W2182487313 @default.
• W185032011 hasVolume "23" @default.
• W185032011 isParatext "false" @default.
• W185032011 isRetracted "false" @default.
• W185032011 magId "185032011" @default.
• W185032011 workType "article" @default.